TABLE 1.
Clinical characteristics of postnatal transmitting and matched nontransmitting HIV-1-infected mothers from the PROMISE 1077BF study
| Characteristica | Values for subjects with indicated transmission status |
|
|---|---|---|
| Transmitter (n = 19) | Nontransmitter (n = 57) | |
| Maternal age (yrs) | ||
| Min–max | 18–38 | 18–36 |
| Median (Q1–Q3) | 24 (23–29) | 26 (23–29) |
| Maternal viral load (log10 copies/ml), first measurement after delivery | ||
| Min–max | 1.48–5.57 | 1.30–5.25 |
| Median (Q1–Q3) | 3.97 (2.52–5.00) | 2.22 (1.60–2.68) |
| Undetectable | 3 (16%) | 17 (30%) |
| Detectable and <1,000 copies/ml | 3 (16%) | 29 (51%) |
| ≥1,000 copies/ml | 13 (68%) | 11 (19%) |
| Maternal viral load (log10 copies/ml), measurement closest to transmission | ||
| Min–max | 1.59–5.47 | 1.28–5.25 |
| Median (Q1–Q3) | 4.20 (3.24–4.96) | 2.15 (1.59–3.31) |
| Undetectable | 1 (5%) | 24 (42%) |
| Detectable and <1,000 copies/ml | 1 (5%) | 13 (23%) |
| ≥1,000 copies/ml | 17 (89%) | 20 (35%) |
| Maternal peripheral CD4+ T cell count (cells/mm3), measurement after delivery | ||
| Min–max | 188–1,337 | 366–1,606 |
| Median (Q1–Q3) | 563 (425–839) | 743 (621–935) |
| Maternal peripheral CD4+ T cell count (cells/mm3), closest to transmission | ||
| Min–max | 270–1,337 | 314–1,606 |
| Median (Q1–Q3) | 560 (436–795) | 743 (628–966) |
| Gestational age at birth (wks) | ||
| Min–max | 35–41 | 30–48 |
| Median (Q1–Q3) | 38 (36–40) | 38 (35–39) |
| Sex of child | ||
| M | 8 (42%) | 22 (39%) |
| F | 11 (58%) | 35 (61%) |
| Maternal parity, including PROMISE delivery | ||
| Min–max | 1–5 | 1–9 |
| Median (Q1–Q3) | 2 (2–3) | 5 (4–6) |
| Country | ||
| India | 1 (5%) | 3 (5%) |
| Malawi | 12 (63%) | 36 (63%) |
| South Africa | 2 (11%) | 6 (11%) |
| Uganda | 4 (21%) | 12 (21%) |
| PP component randomizationb | ||
| Maternal triple ART | 8 (42%) | 26 (46%) |
| Infant prophylaxis | 6 (32%) | 26 (46%) |
| AP observation follow-up | 5 (26%) | 5 (9%) |
| Age of infant at breast milk specimen collection prior to transmission (wks) | ||
| Min–max | 1–74 | 1–74 |
| Median (Q1–Q3) | 26 (6–50) | 26 (6–50) |
| Infant age at infection (wks) | ||
| Min–max | 6–87 | |
| Median (Q1–Q3) | 38 (14–74) | |
a
Min, minimum; max, maximum; M, male; F, female.
b
In the maternal triple-ART arm, the mother received lopinavir-ritonavir (LPV-RTV) plus tenofovir-emtricitabine (TDF/FTC). In the infant prophylaxis arm, the infant received nevirapine (NVP). In the AP observation follow-up, the mother received a triple-ART regimen until the week 1 postpartum visit.